Hcw Biologics INC 8-K filings

HCW Biologics has reached a settlement agreement with Altor BioScience and ImmunityBio, resolving a long-standing arbitration and related legal actions without any monetary payments.

HCW Biologics has received notice from Nasdaq that its market value of listed securities has fallen below the required threshold for continued listing, triggering a compliance period.

HCW Biologics Inc. held its 2024 Annual Meeting of Stockholders, where shareholders elected a Class III director and ratified the appointment of Grant Thornton LLP as the company's independent auditor.

HCW Biologics announced its first quarter 2024 financial results, highlighted by increased revenue and progress in clinical trials, but also noted concerns about its ability to continue as a going concern without additional funding.

HCW Biologics will restate its 2023 financial statements after a criminal scheme led to a $1.3 million loss and revealed a material weakness in internal controls.

HCW Biologics has reported a $1.3 million loss due to a criminal impersonation scheme, impacting a secured note purchase agreement.

HCW Biologics announced its fourth quarter and full year 2023 financial results, highlighting clinical trial progress alongside significant financial losses and ongoing legal challenges.

HCW Biologics has raised $2.5 million through a private placement of common stock to its officers and directors at a premium to the market price.

HCW Biologics terminated its credit agreement with Prime Capital Ventures due to repeated funding delays and is now seeking alternative financing for its facility construction project.